Repair Biotechnologies

Everyone's On Statins. No One Needs To Be.

About this Event

Atherosclerosis – the buildup of cholesterol, fats, and other substances in and on the artery walls –leads to serious health issues including heart disease, aneurysms, kidney disease, and many others. It is the underlying cause of about 50% of all deaths in westernized society. Unfortunately, current treatments like statins can only slow the progression of the disease.

Repair Biotechnologies has developed novel therapies using its proprietary Cholesterol Degrading Platform (CDP) technology that reverses plaque buildup, clearing the arteries, which actually reverses the disease.

CDP is an innovative platform and can be applied to many different indications that involve excess cholesterol in their pathology. These include multi-billion dollar markets with high unmet need, such as atherosclerosis, as well as metabolic dysfunction-associated steatohepatitis (MASH), and orphan conditions such as homozygous familial hypercholesterolemia.

Repair is conducting pre-IND meetings with the FDA in the first half of 2024 to advance these therapies towards clinical trials. This is a first-in-class therapy that is a short term treatment, delivering results in just 6 weeks. It restores homeostasis, preventing one of the most common diseases related to aging and has the potential to reach blockbuster status.

Watch this webinar with Repair Bio leaders to hear how the company’s platform actually reduces disease by degrading free cholesterol from the body.

Video On Demand

– Recorded

July 11


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.